Patents by Inventor Tomohisa Watanabe

Tomohisa Watanabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10676514
    Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 9, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yamashita, Tomohisa Watanabe
  • Publication number: 20200159251
    Abstract: A vehicle includes a communicator configured to receive driving information from a management server, a controller configured to drive the vehicle on the basis of the driving information from the communicator, a manager configured to manage a compartment of the vehicle in which a service user receives a service from a service provider, and an interface set up in association with service-related information provided by the service provider and the compartment.
    Type: Application
    Filed: June 15, 2018
    Publication date: May 21, 2020
    Inventors: Shun Iwasaki, Hisao Asaumi, Kentaro Ishisaka, Izumi Kondo, Satoshi Koike, Tomohisa Manabe, Yo Ito, Yuki Hayashi, Yuji Yasui, Shion Tokunaga, Nobuyuki Watanabe, Kazuki Nishioka, Yudai Hirohata, Hisakazu Yamane, Takayuki Shimoyamada, Kovi Ahego, Liyan Liu, Hirotaka Uchitomi, Masashi Yuki, Takafumi Hirose, Jun Ito, Rie Fukushima, Masaaki Onoda, Christopher Lang
  • Publication number: 20200155596
    Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Application
    Filed: January 27, 2020
    Publication date: May 21, 2020
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya TSUNODA, Ryuji OSAWA, Sachiko YAMASHITA, Tomohisa WATANABE, Tetsuro HIKICHI
  • Patent number: 10640634
    Abstract: A flame retardant resin composition containing a polyolefin resin, a silicone compound, a fatty acid containing compound, aluminum hydroxide, and a triazine ring containing hindered amine compound. With respect to 100 parts by mass of the polyolefin resin, the silicone compound is blended in an amount of the range 0.5 to 10 parts by mass, the fatty acid containing compound is blended in an amount of the range 0.5 to 20 parts by mass, the aluminum hydroxide is blended in an amount of the range 1 to 60 parts by mass, and the triazine ring containing hindered amine compound is blended in an amount of the range 0.05 to 8 parts by mass or less. The triazine ring containing hindered amine compound may include an oxygen atom.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: May 5, 2020
    Assignee: Fujikura Ltd.
    Inventors: Haruka Kohri, Shoichiro Nakamura, Tomohisa Watanabe
  • Publication number: 20200093849
    Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Application
    Filed: December 9, 2019
    Publication date: March 26, 2020
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yamashita, Tomohisa Watanabe, Tetsuro Hikichi
  • Patent number: 10597431
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: March 24, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 10576097
    Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: March 3, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yamashita, Tomohisa Watanabe, Tetsuro Hikichi
  • Patent number: 10576102
    Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: March 3, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yamashita, Tomohisa Watanabe, Tetsuro Hikichi
  • Patent number: 10544293
    Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: January 28, 2020
    Assignee: FUJIKURA LTD.
    Inventors: Haruka Kohri, Masayuki Iwata, Tomohisa Watanabe
  • Publication number: 20200029175
    Abstract: An information processing system using a mobile terminal device includes: a plurality of transmission devices that are distributed over a predetermined region and that transmit mutually different identification information; a receiver, provided in the mobile terminal device, that receives the identification information; an information storage memory that stores device information including, for each of the plurality of transmission devices, the identification information and position information of the transmission device; an input device, provided in the mobile terminal device, that accepts an input of event information related to a subject; an acquisition circuitry that, based on the identification information received by the receive and the position information, acquires the position information of the mobile terminal device at the point in time when the input of the event information was accepted; and an output device that outputs event history information about the subject that includes the event informa
    Type: Application
    Filed: March 2, 2018
    Publication date: January 23, 2020
    Inventors: ATSUSHI FUKUI, YUKI WATANABE, KEI KASAHARA, TOMOHISA YOSHIE, DAISUKE TOYOSHIMA
  • Patent number: 10356276
    Abstract: An image processing apparatus includes a reception unit, an acquisition unit, an enlarging/reducing unit, and a detector. The reception unit receives two image data to be compared. The acquisition unit acquires character sizes of characters contained in the two image data received by the reception unit. The enlarging/reducing unit enlarges or reduces the image data received by the reception unit such that the character sizes of the characters contained in the two image data acquired by the acquisition unit coincide with each other. The detector detects a difference between the two image data which have been enlarged or reduced by the enlarging/reducing unit such that the character sizes of the characters contained in the two image data coincide with each other.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: July 16, 2019
    Assignee: FUJI XEROX CO., LTD.
    Inventors: Tetsuharu Watanabe, Naoyuki Enomoto, Yozo Kashima, Tomohisa Ishikawa
  • Publication number: 20190194829
    Abstract: A coagulated yarn, which is used to manufacture carbon fiber, is a coagulated yarn the surface hole diameter of which is 30 nm or less and the degree of swelling is less than 100% or a coagulated yarn the surface hole diameter of which is 30 nm or less and the inner hole diameter is 30 nm or less. The carbon fiber precursor fiber and the carbon fiber are obtained using such a coagulated yarn.
    Type: Application
    Filed: August 30, 2017
    Publication date: June 27, 2019
    Inventors: Kentaro Kajiwara, Ayanobu Horinouchi, Haruki Okuda, Tomohisa Noguchi, Fumitaka Watanabe
  • Patent number: 10253262
    Abstract: A flame retardant resin composition comprises a polyolefin resin, calcium carbonate particles blended at a ratio of 5 pts. mass to 80 pts. mass, aluminum hydroxide blended at a ratio of 50 pts. mass to 125 pts. mass, a silicone-based compound blended at a ratio of more than 1 pt. mass and 10 pts. mass or less, a fatty acid-containing compound blended at a ratio of 3 pts. mass to 20 pts. mass, and a zinc-containing inorganic compound blended at a ratio of 1 pt. mass to 7 pts. mass, all relative to 100 pts. mass of the polyolefin resin. In the flame retardant resin composition, the calcium carbonate particles and the aluminum hydroxide are blended in total at a ratio of 55 pts. mass to 130 pts. mass relative to 100 pts. mass of the polyolefin resin.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: April 9, 2019
    Assignee: FUJIKURA LTD.
    Inventors: Haruka Kohri, Shoichiro Nakamura, Tomohisa Watanabe
  • Patent number: 10242769
    Abstract: Disclosed is a flame retardant resin composition comprising: a polyolefin resin; a silicone-based compound blended at a ratio of 3 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; calcium carbonate blended at a ratio of 10 parts by mass or more and less than 100 parts by mass relative to 100 parts by mass of the polyolefin resin; and aluminum hydroxide blended at a ratio of 5 parts by mass or more and 60 parts by mass or less relative to 100 parts by mass of the polyolefin resin.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: March 26, 2019
    Assignee: FUJIKURA LTD.
    Inventors: Haruka Kohri, Masayuki Iwata, Tomohisa Watanabe
  • Publication number: 20190023989
    Abstract: Disclosed is a flame retardant resin composition in which relative to 100 parts by mass of the base resin, a silicone based compound is blended at a ratio of 0.1 to 10 parts by mass a fatty acid metal salt is blended at a ratio of 0.1 to 20 parts by mass, a flame retardant agent is blended at a ratio of 5 to 200 parts by mass, a hindered phenol based compound is blended at a ratio of 0.05 to 10 parts by mass, and a hindered amine based compound is blended at a ratio of 0.05 to 10 parts by mass. The hindered amine based compound has a group represented by the following formula (1). (R1 represents an alkyl or alkoxy group having 1 to 30 carbon atoms, and R2 to R5 each independently represent an alkyl group having 1 to 6 carbon atoms).
    Type: Application
    Filed: September 25, 2018
    Publication date: January 24, 2019
    Applicant: FUJIKURA LTD.
    Inventors: Masayuki IWATA, Tomohisa WATANABE
  • Publication number: 20180371220
    Abstract: A flame retardant resin composition containing a polyolefin resin, a silicone compound, a fatty acid containing compound, aluminum hydroxide, and a triazine ring containing hindered amine compound. With respect to 100 parts by mass of the polyolefin resin, the silicone compound is blended in an amount of the range 0.5 to 10 parts by mass, the fatty acid containing compound is blended in an amount of the range 0.5 to 20 parts by mass, the aluminum hydroxide is blended in an amount of the range 1 to 60 parts by mass, and the triazine ring containing hindered amine compound is blended in an amount of the range 0.05 to 8 parts by mass or less. The triazine ring containing hindered amine compound may include an oxygen atom.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 27, 2018
    Applicant: Fujikura Ltd.
    Inventors: Haruka KOHRI, Shoichiro NAKAMURA, Tomohisa WATANABE
  • Publication number: 20180360938
    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 20, 2018
    Inventors: TAKUYA TSUNODA, RYUJI OSAWA, SACHIKO YOSHIMURA, TOMOHISA WATANABE
  • Patent number: 10106743
    Abstract: Disclosed is a flame retardant resin composition in which relative to 100 parts by mass of the base resin, a silicone based compound is blended at a ratio of 0.1 to 10 parts by mass a fatty acid metal salt is blended at a ratio of 0.1 to 20 parts by mass, a flame retardant agent is blended at a ratio of 5 to 200 parts by mass, a hindered phenol based compound is blended at a ratio of 0.05 to 10 parts by mass, and a hindered amine based compound is blended at a ratio of 0.05 to 10 parts by mass. The hindered amine based compound has a group represented by the following formula (1). (R1 represents an alkyl or alkoxy group having 1 to 30 carbon atoms, and R2 to R5 each independently represent an alkyl group having 1 to 6 carbon atoms).
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: October 23, 2018
    Assignee: FUJIKURA LTD.
    Inventors: Masayuki Iwata, Tomohisa Watanabe
  • Patent number: 10092634
    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: October 9, 2018
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Publication number: 20180244903
    Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.
    Type: Application
    Filed: April 26, 2018
    Publication date: August 30, 2018
    Applicant: FUJIKURA LTD.
    Inventors: Haruka KOHRI, Masayuki IWATA, Tomohisa WATANABE